At the news
? BULLISHIMPACT 8/10 8-K filed Apr 6, 2026 at 07:46 ET
Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash, representing a total equity value of $2.9 billion. The acquisition includes Soleno's FDA-approved treatment VYKATTM XR for Prader-Willi syndrome, which generated $190 million in 2025 revenue. The deal is expected to close within 90 days, subject to regulatory approvals and other customary conditions.
- Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash
- Total transaction equity value is $2.9 billion
- VYKATTM XR generated $190 million in 2025 revenue, including $92 million in Q4 2025
- The deal represents a 34% premium to Soleno's closing price on April 2, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access